ERBB2 and breast cancer: A trial evaluating the efficacy and safety of lapatinib plus paclitaxel compared to placebo plus paclitaxel in patients with newly diagnosed HER2+ metastatic BC showed that the addition of lapatinib to paclitaxel significantly improved OS and PFS versus paclitaxel (27.8 vs. 20.5 months, p = 0.0124; 9.7 vs. 6.5 months, p <0.001; respectively) (Guan et al. [15]).